长期应用质子泵抑制剂对非酒精性脂肪肝影响的研究进展
Research Progress of the Effects of Long-Term Use of Proton Pump Inhibitors on Non-Alcoholic Fatty Liver Disease
摘要: 质子泵抑制剂(PPI)是目前最常用的抑酸药物，广泛应用于酸相关胃肠道疾病。同时，PPI的合理使用以及长期使用的安全性问题受到广泛关注。近年来，有研究发现PPI的使用可能会导致肠道微生物群紊乱，增加非酒精性脂肪肝(NAFLD)的患病风险。因此，了解肠道微生物在两者之间的关系至关重要。本文总结了肠道菌群在PPI的使用及NAFLD患病中的影响，以及PPI的长期使用与NAFLD发病的关系，以引起临床医生对长期使用PPI的不良反应关注，旨在为未来基于肠道菌群调节的PPI相关的NAFLD并发症的预防提供参考。
Abstract: Proton pump inhibitors (PPIs) are the most commonly used acid-suppressing drugs and are widely used in acid-related gastrointestinal diseases. Meanwhile, the rational use of PPIs and the safety of long-term use have been extensively concerned. In recent years, some studies have found that PPI use may lead to gut microbiota disruption and increase the risk of non-alcoholic fatty liver disease (NAFLD). Therefore, it is crucial to find out the relationship between the gut microbiota in the two. This article summarizes the influence of gut microbiota in the use of PPIs and the prevalence of NAFLD, as well as the relationship between the long-term use of PPIs and the development of NAFLD, in order to draw the attention of clinicians to the adverse effects of long-term use of PPIs, with the aim of providing a reference for the future prevention of PPI-associated NAFLD complications based on the regulation of the intestinal microbiota.
文章引用：冯琳, 杨朝霞. 长期应用质子泵抑制剂对非酒精性脂肪肝影响的研究进展[J]. 临床医学进展, 2024, 14(4): 1071-1077. https://doi.org/10.12677/acm.2024.1441127

参考文献

[1] Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2012) The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. American Journal of Gastroenterology, 107, 811-826. [Google Scholar] [CrossRef] [PubMed]
[2] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Diabetologia, 59, 1121-1140. [Google Scholar] [CrossRef] [PubMed]
[3] Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M., et al. (2018) Mechanisms of NAFLD Development and Therapeutic Strategies. Nature Medicine, 24, 908-922. [Google Scholar] [CrossRef] [PubMed]
[4] Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. [Google Scholar] [CrossRef] [PubMed]
[5] Freedberg, D.E., Kim, L.S. and Yang, Y.X. (2017) The Risks and Benefits of Long-Term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice from the American Gastroenterological Association. Gastroenterology, 152, 706-715. [Google Scholar] [CrossRef] [PubMed]
[6] Allin, K.H. and Moayyedi, P. (2021) Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander? Gastroenterology, 161, 1789-1791. [Google Scholar] [CrossRef] [PubMed]
[7] Hermos, J.A., Young, M.M., Fonda, J.R., et al. (2012) Risk of Community-Acquired Pneumonia in Veteran Patients to Whom Proton Pump Inhibitors Were Dispensed. Clinical Infectious Diseases, 54, 33-42. [Google Scholar] [CrossRef] [PubMed]
[8] Jandhyala, S.M., Talukdar, R., Subramanyam, C., et al. (2015) Role of the Normal Gut Microbiota. World Journal of Gastroenterology, 21, 8787-8803. [Google Scholar] [CrossRef] [PubMed]
[9] O’May, G.A., Reynolds, N., Smith, A.R., et al. (2005) Effect of pH and Antibiotics on Microbial Overgrowth in the Stomachs and Duodena of Patients Undergoing Percutaneous Endoscopic Gastrostomy Feeding. Journal of Clinical Microbiology, 43, 3059-3065. [Google Scholar] [CrossRef] 
[10] Bruno, G., Zaccari, P., Rocco, G., et al. (2019) Proton Pump Inhibitors and Dysbiosis: Current Knowledge and Aspects to be Clarified. World Journal of Gastroenterology, 25, 2706-2719. [Google Scholar] [CrossRef] [PubMed]
[11] Lo, W.K. and Chan, W.W. (2013) Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 11, 483-490. [Google Scholar] [CrossRef] [PubMed]
[12] Jackson, M.A., Goodrich, J.K., Maxan, M.E., et al. (2016) Proton Pump Inhibitors Alter the Composition of the Gut Microbiota. Gut, 65, 749-756. [Google Scholar] [CrossRef] [PubMed]
[13] Mishiro, T., Oka, K., Kuroki, Y., et al. (2018) Oral Microbiome Alterations of Healthy Volunteers with Proton Pump Inhibitor. Journal of Gastroenterology and Hepatology, 33, 1059-1066. [Google Scholar] [CrossRef] [PubMed]
[14] Imhann, F., Bonder, M.J., Vich Vila, A., et al. (2016) Proton Pump Inhibitors Affect the Gut Microbiome. Gut, 65, 740-748. [Google Scholar] [CrossRef] [PubMed]
[15] Bouwknegt, M., Van Pelt, W., Kubbinga, M.E., et al. (2014) Potential Association between the Recent Increase in Campylobacteriosis Incidence in the Netherlands and Proton-Pump Inhibitor Use—An Ecological Study. Eurosurveillance, 19, Article 20873. [Google Scholar] [CrossRef] 
[16] Leonard, J., Marshall, J.K. and Moayyedi, P. (2007) Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression. The American Journal of Gastroenterology, 102, 2047-2056.
[17] Janarthanan, S., Ditah, I., Adler, D.G., et al. (2012) Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis. The American Journal of Gastroenterology, 107, 1001-1010. [Google Scholar] [CrossRef] [PubMed]
[18] Imhann, F., Vich Vila, A., Bonder, M.J., et al. (2017) The Influence of Proton Pump Inhibitors and Other Commonly Used Medication on the Gut Microbiota. Gut Microbes, 8, 351-358. [Google Scholar] [CrossRef] [PubMed]
[19] Freedberg, D.E., Toussaint, N.C., Chen, S.P., et al. (2015) Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology, 149, 883-885. [Google Scholar] [CrossRef] [PubMed]
[20] Zhu, J., Sun, C., Li, M., et al. (2023) Compared to Histamine-2 Receptor Antagonist, Proton Pump Inhibitor Induces Stronger Oral-to-Gut Microbial Transmission and Gut Microbiome Alterations: A Randomised Controlled Trial. https://gut.bmj.com/content/early/2023/11/22/gutjnl-2023-330168 [Google Scholar] [CrossRef] [PubMed]
[21] Chen, J. and Vitetta, L. (2020) Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. International Journal of Molecular Sciences, 21, Article 5214. [Google Scholar] [CrossRef] [PubMed]
[22] Chen, J. and Vitetta, L. (2020) Butyrate in Inflammatory Bowel Disease Therapy. Gastroenterology, 158, 1511. [Google Scholar] [CrossRef] [PubMed]
[23] Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., et al. (2020) Gut Microbiota and Human NAFLD: Disentangling Microbial Signatures from Metabolic Disorders. Nature Reviews Gastroenterology & Hepatology, 17, 279-297. [Google Scholar] [CrossRef] [PubMed]
[24] Zhai, Q., Wu, H., Zheng, S., et al. (2023) Association between Gut Microbiota and NAFLD/NASH: A Bidirectional Two-Sample Mendelian Randomization Study. Frontiers in Cellular and Infection Microbiology, 13, Article 1294826. [Google Scholar] [CrossRef] [PubMed]
[25] Schwimmer, J.B., Johnson, J.S., Angeles, J.E., et al. (2019) Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children with Nonalcoholic Fatty Liver Disease. Gastroenterology, 157, 1109-1122. [Google Scholar] [CrossRef] [PubMed]
[26] Gómez-Pérez, A.M., Ruiz-Limón, P., Salas-Salvadó, J., et al. (2023) Gut Microbiota in Nonalcoholic Fatty Liver Disease: A PREDIMED-Plus Trial Sub Analysis. Gut Microbes, 15, Article 2223339. [Google Scholar] [CrossRef] [PubMed]
[27] Boursier, J., Mueller, O., Barret, M., et al. (2016) The Severity of NAFLD Is Associated with Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. Hepatology, 63, 764-775. [Google Scholar] [CrossRef] [PubMed]
[28] Son, G., Kremer, M. and Hines, I.N. (2010) Contribution of Gut Bacteria to Liver Pathobiology. Gastroenterology Research and Practice, 2010, Article ID: 453563. [Google Scholar] [CrossRef] [PubMed]
[29] Chiu, C.C., Ching, Y.H., Li, Y.P., et al. (2017) Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients, 9, Article 1220. [Google Scholar] [CrossRef] [PubMed]
[30] Campo, L., Eiseler, S., Apfel, T., et al. (2019) Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. Journal of Clinical and Translational Hepatology, 7, 56-60. [Google Scholar] [CrossRef] 
[31] Baumann, A., Jin, C.J., Brandt, A., et al. (2020) Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis. Nutrients, 12, Article 951. [Google Scholar] [CrossRef] [PubMed]
[32] Pyo, J.H., Kim, T.J., Lee, H., et al. (2021) Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease: A Nationwide Cohort Study. Journal of Gastroenterology and Hepatology, 36, 1235-1243. [Google Scholar] [CrossRef] [PubMed]
[33] Imperatore, N., Tortora, R., Testa, A., et al. (2018) Proton Pump Inhibitors as Risk Factor for Metabolic Syndrome and Hepatic Steatosis in Coeliac Disease Patients on Gluten-Free Diet. Journal of Gastroenterology, 53, 507-516. [Google Scholar] [CrossRef] [PubMed]
[34] Huang, H., Liu, Z., Guo, Y., et al. (2023) Long-Term Use of Proton Pump Inhibitors Is Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 58, 289-296. https://journals.lww.com/10.1097/MCG.0000000000001847 [Google Scholar] [CrossRef] 
[35] Llorente, C., Jepsen, P., Inamine, T., et al. (2017) Gastric Acid Suppression Promotes Alcoholic Liver Disease by Inducing Overgrowth of Intestinal Enterococcus. Nature Communications, 8, Article No. 837. [Google Scholar] [CrossRef] [PubMed]
[36] Saad, M.J.A., Santos, A. and Prada, P.O. (2016) Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. Physiology, 31, 283-293. [Google Scholar] [CrossRef] [PubMed]
[37] Tsukumo, D.M., Carvalho, B.M., Carvalho Filho, M.A., et al. (2015) Translational Research into Gut Microbiota: New Horizons on Obesity Treatment: Updated 2014. Archives of Endocrinology and Metabolism, 59, 154-160. [Google Scholar] [CrossRef] [PubMed]
[38] Jiao, N., Baker, S.S., Nugent, C.A., et al. (2018) Gut Microbiome May Contribute to Insulin Resistance and Systemic Inflammation in Obese Rodents: A Meta-Analysis. Physiological Genomics, 50, 244-254. [Google Scholar] [CrossRef] [PubMed]
[39] Zhi, C., Huang, J., Wang, J., et al. (2019) Connection between Gut Microbiome and the Development of Obesity. European Journal of Clinical Microbiology & Infectious Diseases, 38, 1987-1998. [Google Scholar] [CrossRef] [PubMed]
[40] Assalin, H.B., De Almeida, K.C.G., Guadagnini, D., et al. (2022) Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver. International Journal of Molecular Sciences, 23, Article 13766. [Google Scholar] [CrossRef] [PubMed]
[41] Natividad, J.M., Lamas, B., Pham, H.P., et al. (2018) Bilophila wadsworthia Aggravates High Fat Diet Induced Metabolic Dysfunctions in Mice. Nature Communications, 9, Article No. 2802. [Google Scholar] [CrossRef] [PubMed]
[42] Brun, P., Castagliuolo, I., Di Leo, V., et al. (2007) Increased Intestinal Permeability in Obese Mice: New Evidence in the Pathogenesis of Nonalcoholic Steatohepatitis. American Journal of Physiology. American Journal of Physiology-Gastrointestinal and Liver Physiology, 292, G518-G525. [Google Scholar] [CrossRef] [PubMed]
[43] Miele, L., Valenza, V., La Torre, G., et al. (2009) Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease. Hepatology, 49, 1877-1887. [Google Scholar] [CrossRef] [PubMed]
[44] Sharifnia, T., Antoun, J., Verriere, T.G.C., et al. (2015) Hepatic TLR4 Signaling in Obese NAFLD. American Journal of Physiology-Gastrointestinal and Liver Physiology, 309, G270-G278. [Google Scholar] [CrossRef] [PubMed]
[45] Kolodziejczyk, A.A., Zheng, D., Shibolet, O., et al. (2019) The Role of the Microbiome in NAFLD and NASH. EMBO Molecular Medicine, 11, e9302. [Google Scholar] [CrossRef] [PubMed]
[46] Seki, E., De Minicis, S., Osterreicher, C.H., et al. (2007) TLR4 Enhances TGF-β Signaling and Hepatic Fibrosis. Nature Medicine, 13, 1324-1332. [Google Scholar] [CrossRef] [PubMed]

为你推荐